Jun 2026 (Q2 FY26) — Aug 5, 2026
Onterris Q2 FY26 — Strategic Review Initiated Amidst Lower Revenue Outlook and Strong Profitability
Read the full callOnterris (ONT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Onterris earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 187 | −20.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 3.5 | −2.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.4 | −92.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$13.82 −1.36% · −$0.19
Performance −38.6% YTD
YTD: $22.51 on 7 Apr 2026 → $13.82. High $22.85 (4 Aug 2026), low $12.71 (2 Oct 2026).
- Previous close
- $14.01
- 52-week range
- $12.71 – $22.85
Overview
- Symbol
- ONT
- Sector
- Industrials
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Onterris earnings calls (ONT)
Financials
What the filings say
Net profit, year on year: −93% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 179 | 189 | 178 | 235 | 225 | 193 | 169 | 187 |
| Operating profit | -1 | -23 | -11 | 15 | 10 | -3 | -6 | 6 |
| Operating margin | −0.7% | −12.1% | −6.0% | 6.4% | 4.4% | −1.3% | −3.6% | 3.5% |
| Other income | -8 | -2 | -6 | 4 | 6 | -5 | -4 | -5 |
| Profit before tax | -9 | -25 | -16 | 19 | 16 | -7 | -10 | 2 |
| Tax rate | −14.9% | −14.2% | −17.4% | 5.1% | 46.5% | −12.7% | −22.2% | 20.2% |
| Net profit | -11 | -28 | -19 | 18 | 8 | -8 | -13 | 1 |
| EPS ($ per share) | -0.39 | — | -0.64 | 0.48 | 0.24 | — | -0.35 | 0.04 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | — | — | — | — | — | 0 |
| Reserves | — | -64 | -122 | -148 | -179 | -210 | -273 | -274 |
| Total liabilities | — | 229 | 313 | 364 | 326 | 343 | 451 | 530 |
| Fixed assets | — | 27 | 34 | 32 | 36 | 57 | 64 | 64 |
| Total assets | — | 332 | 603 | 833 | 792 | 817 | 990 | 981 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3 | 17 | 2 | 38 | 21 | 56 | 22 | 107 |
| Cash from investing | -50 | -87 | -180 | -72 | -39 | -102 | -138 | -16 |
| Cash from financing | 51 | 74 | 206 | 146 | -39 | -20 | 106 | -93 |
| Capital expenditure | -4 | -5 | -8 | -7 | -10 | -30 | -21 | -16 |
| Free cash flow | -7 | 12 | -6 | 31 | 11 | 26 | 1 | 91 |
Insider filings
39 filings between Nov 10, 2025 and Jun 5, 2026.
Open market
decisions to buy or sellPurchases
$610.0K
3 purchases by 2 insiders
Sales
$7.96M
12 sales by 4 insiders
58% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 9
- Award — granted as compensation
- 10
- Option exercise — converted options into shares
- 4
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Manthripragada Vijay | — | $3.37M | Mar 13, 2026 |
| Revuelta Jose | — | $3.07M | Mar 9, 2026 |
| Afsari Nasym | — | $1.24M | Mar 3, 2026 |
| GRAHAM PETER | $509.6K | — | Jun 5, 2026 |
| PRESBY J THOMAS | — | $288.7K | Mar 2, 2026 |
| Dicks Allan | $100.4K | — | May 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | GRAHAM PETER Director | Purchase | 25,140 | $432.2K |
| Jun 3, 2026 | GRAHAM PETER Director | Purchase | 4,860 | $77.5K |
| May 11, 2026 | Dicks Allan Chief Financial Officer | Purchase | 6,535 | $100.4K |
| May 11, 2026 | Revuelta Jose Chief Strategy Officer | Option exercise | 27,349 | $164.9K |
| Mar 13, 2026 | PERLMAN RICHARD E Director | Gift | 74,461 | $0 |
| Mar 13, 2026 | Manthripragada Vijay President & CEO | Option exercise 10b5-1 plan | 33,166 | $200.0K |
| Mar 13, 2026 | Manthripragada Vijay President & CEO | Option exercise 10b5-1 plan | 85,992 | $518.5K |
| Mar 13, 2026 | Manthripragada Vijay President & CEO | Sale 10b5-1 plan | 46,121 | $1.17M |
| Mar 11, 2026 | Laws James Chief Operating Officer | Award | 18,761 | $0 |
| Mar 9, 2026 | Revuelta Jose Chief Strategy Officer | Sale | 7,858 | $212.2K |
| Mar 9, 2026 | Revuelta Jose Chief Strategy Officer | Option exercise | 7,858 | $47.4K |
| Mar 4, 2026 | Revuelta Jose Chief Strategy Officer | Option exercise | 42,668 | $257.3K |
| Mar 4, 2026 | Revuelta Jose Chief Strategy Officer | Sale | 42,668 | $1.18M |
| Mar 3, 2026 | Revuelta Jose Chief Strategy Officer | Option exercise | 60,000 | $361.8K |
| Mar 3, 2026 | Revuelta Jose Chief Strategy Officer | Sale | 60,000 | $1.68M |
| Mar 3, 2026 | Afsari Nasym General Counsel and Secretary | Option exercise 10b5-1 plan | 43,348 | $261.4K |
| Mar 3, 2026 | Afsari Nasym General Counsel and Secretary | Sale 10b5-1 plan | 43,348 | $1.23M |
| Mar 2, 2026 | PRESBY J THOMAS Director | Sale | 459 | $13.7K |
| Mar 2, 2026 | PRESBY J THOMAS Director | Option exercise | 10,000 | $97.6K |
| Mar 2, 2026 | PRESBY J THOMAS Director | Sale | 9,541 | $275.0K |
| Mar 2, 2026 | Afsari Nasym General Counsel and Secretary | Sale 10b5-1 plan | 200 | $6.0K |
| Jan 1, 2026 | GRAHAM PETER Director | Award | 4,430 | $0 |
| Jan 1, 2026 | PRICE JAMES K Director | Award | 4,430 | $0 |
| Jan 1, 2026 | PERLMAN RICHARD E Director | Award | 4,430 | $0 |
| Jan 1, 2026 | Field Janet Risi Director | Award | 4,430 | $0 |
| Jan 1, 2026 | Fernandez de Castro Jose Miguel Director | Award | 4,430 | $0 |
| Jan 1, 2026 | PRESBY J THOMAS Director | Award | 4,430 | $0 |
| Jan 1, 2026 | Newmark Robin Director | Award | 4,430 | $0 |
| Jan 1, 2026 | Colman Vincent Director | Award | 4,430 | $0 |
| Dec 16, 2025 | Manthripragada Vijay President & CEO | Tax withheld | 152,886 | $4.04M |
| Dec 16, 2025 | Revuelta Jose Chief Strategy Officer | Tax withheld | 46,216 | $1.22M |
| Dec 16, 2025 | Dicks Allan Chief Financial Officer | Tax withheld | 60,813 | $1.61M |
| Dec 16, 2025 | Afsari Nasym General Counsel and Secretary | Tax withheld | 60,813 | $1.61M |
| Nov 11, 2025 | Manthripragada Vijay President & CEO | Sale 10b5-1 plan | 44,984 | $1.08M |
| Nov 11, 2025 | Manthripragada Vijay President & CEO | Option exercise 10b5-1 plan | 44,984 | $271.3K |
| Nov 10, 2025 | Manthripragada Vijay President & CEO | Sale 10b5-1 plan | 5,072 | $129.9K |
| Nov 10, 2025 | Manthripragada Vijay President & CEO | Sale 10b5-1 plan | 112 | $2.9K |
| Nov 10, 2025 | Manthripragada Vijay President & CEO | Option exercise 10b5-1 plan | 44,983 | $271.2K |
| Nov 10, 2025 | Manthripragada Vijay President & CEO | Sale 10b5-1 plan | 39,799 | $980.1K |
| May 13, 2025 | Colman Vincent Director | Purchase | 2,600 | $49.0K |
| Mar 11, 2025 | Colman Vincent Director | Award | 5,396 | $0 |
| Mar 6, 2025 | Fernandez de Castro Jose Miguel Director | Purchase | 10,000 | $180.7K |
| Jan 1, 2025 | Field Janet Risi Director | Award | 5,929 | $0 |
| Jan 1, 2025 | Fernandez de Castro Jose Miguel Director | Award | 5,929 | $0 |
| Jan 1, 2025 | Newmark Robin Director | Award | 5,929 | $0 |
| Jan 1, 2025 | PERLMAN RICHARD E Director | Award | 5,929 | $0 |
| Jan 1, 2025 | PRESBY J THOMAS Director | Award | 5,929 | $0 |
| Jan 1, 2025 | GRAHAM PETER Director | Award | 5,929 | $0 |
| Jan 1, 2025 | PRICE JAMES K Director | Award | 5,929 | $0 |
| Nov 21, 2024 | PRESBY J THOMAS Director | Award | 5,000 | $98.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Onterris, Inc.
Free account. Everything above stays public.
Write why you follow Onterris, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading